<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;AASLD practice guidelines: the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Boyer T, Haskal Z, American Association for the Study of Liver Disease (AASLD). AASLD practice guidelines: the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. Hepatology. 2010 Jan;51(1):1-16. [127 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005 Feb;41(2):386-400.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Hemorrhage of gastrointestinal tract, unspecified  (578.9); Hepatopulmonary syndrome  (573.5); Hepatorenal syndrome  (572.4); Portal hypertension  (572.3)"/><FieldValue Value="MSH: Ascites ; Esophageal and Gastric Varices ; Gastric Antral Vascular Ectasia ; Gastrointestinal Hemorrhage ; Hepatic Veno-Occlusive Disease ; Hepatopulmonary Syndrome ; Hepatorenal Syndrome ; Hydrothorax ; Hypertension, Portal ; Kidney Function Tests ; Liver Cirrhosis ; Liver Function Tests ; Magnetic Resonance Imaging ; Portasystemic Shunt, Transjugular Intrahepatic ; Stomach Diseases ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed ; Ultrasonography, Doppler ; Ultrasonography, Doppler, Duplex "/><FieldValue Value="MTH: Ascites ; Computed Tomography Scanning Systems ; Gastrointestinal Hemorrhage ; Hepatic Vein Thrombosis ; Hepatic Veno-Occlusive Disease ; Hepatorenal Syndrome ; Kidney Function Tests ; Liver Cirrhosis ; Liver Function Tests ; Magnetic Resonance Imaging ; Shunt Device ; Stomach Diseases ; Transjugular intrahepatic portosystemic shunt procedure ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: computed tomography ; magnetic resonance imaging "/><FieldValue Value="SNOMEDCT_US: Ascites  (389026000); Cirrhosis of liver  (19943007); Computerized axial tomography  (77477000); Disorder of stomach  (29384001); Duplex ultrasound  (312236008); Gastrointestinal hemorrhage  (74474003); Hepatic vein thrombosis  (38739001); Hepatopulmonary syndrome  (371067004); Hepatorenal syndrome  (51292008); Hydrothorax  (79231000); Liver function tests - general  (26958001); Liver function tests - general  (271552009); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Portal hypertension  (34742003); Renal function study  (44277000); Shunt  (257351008); Transjugular intrahepatic portosystemic shunt  (233445008); Vascular ectasia of gastric antrum  (43935004); Veno-occlusive disease of the liver  (65617004)"/><FieldValue Value="SPN: SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC ; SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Magnetic Resonance Imaging  (16-260); Scanning Systems, Ultrasonic  (14-278); Shunts  (13-585)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Complications of portal hypertension:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Esophageal and gastric variceal bleeding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Portal hypertensive gastropathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gastric antral vascular ectasia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cirrhotic ascites &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Refractory hepatic hydrothorax &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatorenal syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Budd-Chiari syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatic encephalopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatopulmonary syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Veno-occlusive disease or sinusoidal obstruction syndrome &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Assessment of Therapeutic Effectiveness" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Critical Care" /><FieldValue Value="Gastroenterology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Radiology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Health Care Providers" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide a data-supported approach to the use of transjugular intrahepatic portosystemic shunt (TIPS) in the management of the complications of portal hypertension&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patient with complications of portal hypertension&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pre-transjugular intrahepatic portasystemic shunt (TIPS) evaluation, including routine tests of liver and kidney function; cross-sectional imaging of the liver by Duplex ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI); and cardiac evaluation (only when indicated) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Creation and placement of TIPS&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Post-TIPS monitoring by Doppler ultrasound and follow-up to monitor for TIPS dysfunction &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Success rate of transjugular intrahepatic portosystemic shunt (TIPS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rebleeding rates/reoccurrence of problem for which TIPS was originally inserted&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complications of TIPS &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A MEDLINE search was performed from 1966 to 2009. A total of 1143 articles were found under the subject heading &quot;transjugular intrahepatic portosystemic shunt.&quot; Controlled trials and large series were sought during this search. Recently published papers were also used as a source of references missed by the MEDLINE search, and the personal files of the two authors were also used as a source of references.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grade I&lt;/strong&gt;: Randomized controlled trials&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-1&lt;/strong&gt;: Controlled trials without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-2&lt;/strong&gt;: Cohort or case-control analytic studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-3&lt;/strong&gt;: Multiple time series, dramatic uncontrolled experiments&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade III&lt;/strong&gt;: Opinions of respected authorities, descriptive epidemiology&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A cost-effectiveness analysis of a randomized controlled trial comparing transjugular intrahepatic portosystematic shunt (TIPS) (bare metal Wallstents) to distal splenorenal shunt (DSRS) reported costs of both in- and out-patient care. The average yearly cost over a 5 year period were $16,363 for TIPS patients and $13,492 for the DSRS patients. These yearly costs are similar to what has been reported for pharmacologic and endoscopic management of patients with bleeding varices. TIPS was slightly more cost effective than DSRS at year five ($61,000 per life saved) but difference was felt not to be significant. Using covered rather than bare walls stents was estimated to increase the cost-effectiveness of TIPS only slightly. The authors conclude that TIPS is as effective as DSRS in the prevention of variceal rebleeding and may be slightly more cost-effective.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Practice Guidelines Committee of the American Association for the Study of Liver Diseases (AASLD) provided extensive peer review of the manuscript. These recommendations are fully endorsed by the AASLD and the Society for Interventional Radiology.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Recommendations are followed by quality of evidence ratings (&lt;strong&gt;Grades I, II-1, II-2, II-3, III&lt;/strong&gt;) which are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;The Procedure: Pre-TIPS Evaluation and Contraindications, Mortality&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Transjugular intrahepatic portosystemic shunt (TIPS) should only be performed by experienced interventional radiologists (or specially trained physicians). Success and complication rates should be monitored and if they fail to meet expected rates then review of the program should be considered &lt;strong&gt;(Grade III)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The decision to perform a TIPS, especially in a high-risk patient, should be reached by a team consisting of a gastroenterologist/hepatologist, interventional radiologist, and, where appropriate, a transplant physician &lt;strong&gt;(Grade III)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Preceding creation of a TIPS, tests of liver and kidney function should be performed as well as  cross-sectional imaging of the liver to assess portal system patency and exclude liver masses &lt;strong&gt;(Grade III)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction in hepatic venous pressure gradient (HVPG) to less than 12 mm Hg should be achieved when the indication is bleeding esophageal varices. Embolization of gastric varices may be required despite adequate decompression of the portal venous system &lt;strong&gt;(Grade II-2)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The degree of reduction in HVPG to control ascites is unclear, but at present a gradient of at least 12 mm Hg or less has been suggested to be a reasonable goal &lt;strong&gt;(Grade II-2)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with high predicted 30-day mortalities (Model for End-Stage Liver Disease [MELD] &amp;gt; 15 to 18 or serum bilirubin &amp;gt; 4.0 mg/dL) should be informed of their prognosis, and TIPS performed only in the absence of other options &lt;strong&gt;(Grade II-2)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In high-risk patients, the need for liver transplantation should be discussed before the performance of an elective TIPS &lt;strong&gt;(Grade III)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Complications; TIPS in the Transplant Candidate&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;Those performing TIPS need to be aware of both the procedural complications and  those due to portal diversion and be experienced in their management &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Each center performing TIPS should have an established program of TIPS surveillance, and although there are no established guidelines, Doppler ultrasound should be performed at specified intervals following the procedure and the yearly anniversary of the TIPS thereafter &lt;strong&gt;(Grade II-1)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ultrasonographic findings suggesting TIPS dysfunction or recurrence of the complication of portal hypertension that lead to the initial TIPS should lead to repeat shunt venography and intervention, as indicated. The recurrence of symptoms in the face of a &quot;normal&quot; ultrasound does not eliminate the need for TIPS venography &lt;strong&gt;(Grade II-2)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;TIPS stenosis is common when bare stents have been used, especially in the first year, and Doppler ultrasound lacks the sensitivity and specificity needed to identify many of these patients. Therefore, repeat catheterization of the TIPS or upper endoscopy should be considered at the 1-year anniversary of TIPS creation, especially in those patients who bled from varices &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Polytetrafluoroethylene (ePTFE)-covered stents are preferred to bare stents to lower the risk of shunt dysfunction. &lt;strong&gt;(Grade-I)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As with any form of portosystemic diversion, the risk of developing hepatic encephalopathy is increased following TIPS creation. The prophylactic use of nonabsorbable disaccharides or antibiotics does not appear to lower this risk. &lt;strong&gt;(Grade-I)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Indications&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Primary Prevention of Variceal Bleeding; Acutely Bleeding Esophageal Varices Refractory to Medical Treatment; Esophageal Variceal Rebleeding; Bleeding from Gastric Varices; Prevention of Bleeding From Portal Hypertensive Gastropathy (PHG) and Gastric Antral Vascular Ectasia (GAVE)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;14&quot;&gt;&#xD;&#xA;    &lt;li&gt;The use of TIPS to prevent bleeding from varices that have never bled is contraindicated because of the risk of increasing morbidity and mortality &lt;strong&gt;(Grade III)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;TIPS is effective in controlling acute bleeding from varices that is refractory to medical therapy and TIPS should be used in preference to surgery &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pending the development of tests that accurately predict the risk of rebleeding, TIPS should not be used for the prevention of rebleeding in patients who have bled only once from esophageal varices. Its use should be limited to those who fail pharmacological and endoscopic therapy &lt;strong&gt;(Grade I)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;TIPS is effective in the prevention of rebleeding from gastric and ectopic varices (including intestinal, stomal, and anorectal varices) and is the preferred approach for the prevention of rebleeding in this group of patients &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients with good liver function, either a TIPS or a surgical shunt are appropriate choices for the prevention of rebleeding in patients who have failed medical therapy &lt;strong&gt;(Grade I)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients with poor liver function, TIPS is preferred to surgical therapy in the prevention of rebleeding in patients who have failed medical therapy &lt;strong&gt;(Grade III)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of TIPS in the management of portal hypertensive gastropathy should be limited to those who have recurrent bleeding despite the use of beta-blockers &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;TIPS is ineffective in controlling bleeding from gastric antral vascular ectasia in patients with cirrhosis and should not be used in this situation &lt;strong&gt;(Grade II-3)&lt;/strong&gt;.&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cirrhotic Ascites; Refractory Hepatic Hydrothorax; Hepatorenal Syndrome (HRS)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;22&quot;&gt;&#xD;&#xA;    &lt;li&gt;TIPS will decrease the need for repeated large-volume paracentesis in patients with refractory cirrhotic ascites. However, given the uncertainty as to the effect of TIPS creation on survival and the increased risk of encephalopathy, TIPS should be used in those patients who are intolerant of repeated large-volume paracentesis &lt;strong&gt;(Grade I)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;TIPS is effective in the control of hepatic hydrothorax, but it only should be used in patients whose effusion cannot be controlled by diuretics and sodium restriction &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;TIPS is of investigatory use for the treatment of hepatorenal syndrome (HRS), especially type 1, pending the publication of controlled trials &lt;strong&gt;(Grade II-3)&lt;/strong&gt;.&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Budd-Chiari Syndrome (BCS); Veno-occlusive Disease or Sinusoidal Obstruction Syndrome (SOS); Hepatopulmonary Syndrome&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;25&quot;&gt;&#xD;&#xA;    &lt;li&gt;The decision to create a TIPS in a patient with Budd-Chiari syndrome should be based on the severity of disease, and only those with moderate disease and who have failed to respond to anticoagulation appear to be reasonable candidates for a TIPS &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with Budd-Chiari syndrome and mild disease can be managed medically, whereas those with more severe disease or acute hepatic failure are best managed by liver transplantation &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of TIPS to treat sinusoidal obstruction syndrome (SOS) cannot be recommended &lt;strong&gt;(Grade II-3)&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of TIPS to treat hepatopulmonary syndrome is not recommended &lt;strong&gt;(Grade II-3)&lt;/strong&gt;.&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Conclusions&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;TIPS is an important part of the current armamentarium used to treat the complications of portal hypertension. Most fellowship-trained interventional radiologists are capable of creating a TIPS in a patient with patent hepatic and portal veins. Creation of a TIPS ranks among the more complex procedures performed by interventional radiologists, and it is important that each physician monitor their success and complication rates. As with any complex intervention, the decision to create a TIPS should be reached by a gastroenterologist or hepatologist who is experienced in the management of these patients in concert with an interventional radiologist. Pre-TIPS evaluation includes routine tests of liver and kidney function as well as Doppler ultrasound, contrast-enhanced abdominal computed tomography (CT), or magnetic resonance imaging (MRI) of the liver. Once a TIPS is created, it cannot be forgotten. The patient requires frequent monitoring by Doppler ultrasound and clinic visits to look for the development of TIPS dysfunction. The use of polytetrafluoroethylene (PTFE)-covered stents reduces the risk of TIPS dysfunction, but this will not eliminate the need for continued surveillance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;TIPS will effectively prevent rebleeding from varices and decrease the need for repeat thoracentesis in patients with hepatic hydrothorax or for large-volume paracentesis in patients with refractory ascites. However, TIPS will increase the incidence of hepatic encephalopathy and will not improve survival in any of these patients. Hence, TIPS should not be considered as primary therapy for any complication of portal hypertension with the exception of bleeding gastric or ectopic varices. In all other situations, TIPS should only be created when the patient has failed other forms of medical therapy (i.e., pharmacological or endoscopic therapy, diuretics, or repeated large-volume paracentesis or thoracentesis). In patients with good liver function and recurrent bleeding from varices despite medical treatment, a surgical shunt or TIPS appear to be equivalent therapies. Which patients with BCS are best managed by TIPS remains undefined, although creation of a TIPS in select patients appears to be of benefit. Creation of a TIPS for the treatment of hepatorenal syndrome (HRS) or hepatopulmonary syndrome is of unproven benefit and should be considered investigatory.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade I&lt;/strong&gt;: Randomized controlled trials&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-1&lt;/strong&gt;: Controlled trials without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-2&lt;/strong&gt;: Cohort or case-control analytic studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-3&lt;/strong&gt;: Multiple time series, dramatic uncontrolled experiments&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade III&lt;/strong&gt;: Opinions of respected authorities, descriptive epidemiology&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appropriate selection of patients for and use of the transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of complications of portal hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Control of acute bleeding from varices that are refractory to medical therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevention of rebleeding from gastric and ectopic varices &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Decrease in the need for repeat thoracentesis in patients with hepatic hydrothorax or for large-volume paracentesis in patients with refractory ascites &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Complications of Transjugular Intrahepatic Portosystemic Shunt (TIPS)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;TIPS dysfunction (thrombosis, occlusion/stenosis) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Transcapsular puncture&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intraperitoneal bleed&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatic infarction&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fistulae&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hemobilia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sepsis&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Infection of TIPS&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hemolysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Encephalopathy&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stent migration or placement into inferior vena cava or too far into portal vein&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Absolute Contraindications to Placement of a Transjugular Intrahepatic Portosystemic Shunt (TIPS)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Primary prevention of variceal bleeding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Congestive heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Multiple hepatic cysts &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Uncontrolled systemic infection or sepsis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Unrelieved biliary obstruction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe pulmonary hypertension &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Relative Contraindications to Placement of a TIPS&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hepatoma, especially if central &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obstruction of all hepatic veins &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Portal vein thrombosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe coagulopathy (international normalized ratio [INR] &amp;gt;5) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thrombocytopenia of less than 20,000/cm&lt;sup&gt;3&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate pulmonary hypertension &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;These recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies designed to be followed in every case. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Which patients with Budd-Chiari syndrome (BCS) are best managed by transjugular intrahepatic portosystemic shunts (TIPS) remains undefined, although creation of a TIPS in select patients may be of benefit. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Creation of a TIPS for the treatment of hepatorenal syndrome (HRS) or hepatopulmonary syndrome is of unproven benefit and should be considered investigatory. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Mobile Device Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Boyer T, Haskal Z, American Association for the Study of Liver Disease (AASLD). AASLD practice guidelines: the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. Hepatology. 2010 Jan;51(1):1-16. [127 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2005 Feb (revised 2010 Jan)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Association for the Study of Liver Diseases - Nonprofit Research Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Association for the Study of Liver Diseases&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Practice Guidelines Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Primary Authors&lt;/em&gt;: Thomas D. Boyer, Liver Research Institute, University of Arizona School of Medicine, Tucson, AZ; Ziv J. Haskal, Division of Vascular and Interventional Radiology, University of Maryland Medical School, Baltimore, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Committee Members&lt;/em&gt;: Jayant A. Talwalkar, MD, MPH (&lt;em&gt;Chair&lt;/em&gt;); Anna Mae Diehl, MD (Board Liaison); Jeffrey H. Albrecht, MD; Amanda DeVoss, MMS, PA-C; Jose Franco, MD; Stephen A. Harrison, MD; Kevin  Korenblat, MD; Simon C. Ling, MBChB; Lawrence U. Liu, MD; Paul Martin, MD; Kim M. Olthoff, MD; Robert S. O'Shea, MD; Nancy Reau, MD; Adnan Said, MD; Margaret C. Shuhart, MD, MS; and Kerry N. Whitt, MD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drs. Boyer and Haskal were paid consultants for W. L. Gore and Associates, Inc., the manufacturer of a polytetrafluoroethylene (PTFE)-covered stent used for transjugular intrahepatic portosystemic shunts (TIPS).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist"><FieldValue Value="Society of Interventional Radiology - Medical Specialty Society" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005 Feb;41(2):386-400.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/TIPS%20Update%20Nov%202009.pdf&quot; title=&quot;AASLD Web site&quot; target=&quot;_blank&quot;&gt;American Association for the Study of Liver Diseases Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Association for the Study of Liver Diseases, 1729 King Street, Suite 200; Alexandria, VA 22314; Phone: 703-299-9766; Web site: &lt;a href=&quot;http://www.aasld.org&quot; target=&quot;_blank&quot;&gt;www.aasld.org&lt;/a&gt;; e-mail: &lt;a href=&quot;mailto:aasld@aasld.org&quot;&gt;aasld@aasld.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is available as a Personal Digital Assistant (PDA) download via the APPRISOR&lt;sup&gt;&amp;trade;&lt;/sup&gt; Document Viewer from &lt;a href=&quot;http://www.apprisor.com&quot; title=&quot;APPRISOR Document Viewer&quot; target=&quot;_blank&quot;&gt;www.apprisor.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on May 17, 2005. The information was verified by the guideline developer on June 13, 2005. This NGC summary was updated by ECRI Institute on February 28, 2010. The updated information was verified by the guideline developer on March 24, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the American Association for the Study of Liver Diseases' copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
